Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Key Takeaways Tirzepatide vs semaglutide comes down to dual agonist vs single agonist: tirzepatide targets both GLP-1 and GIP receptors, while semaglutide targets GLP-1 alone The only head-to-head trial (SURPASS-2) found tirzepatide superior to semaglutide for both blood sugar control and weight loss In separate obesity trials, tirzepatide 15mg achieved 20.9% weight loss at 72 weeks vs semaglutide 2.4mg's 14.9% at 68 weeks Semaglutide has proven cardiovascular benefit (SELECT trial: 20% MACE reduction)
People who plan ahead report a better experience when switching from Tirzepatide to Retatrutide compared to those who go in unprepared
When were going through insurance, there might be more things, requirements that have to be met. And hes frank about what drives most of the questions he gets: The biggest issue is usually cost and access. The practical takeaway cuts both ways
[3][4] For practitioners evaluating Retatrutide alternatives for weight loss, the primary approved options are Tirzepatide, an FDA-approved dual GLP-1/GIP receptor agonist (Mounjaro/Zepbound), and Semaglutide, an FDA-approved GLP-1 receptor agonist (Ozempic/Wegovy)
US$ 28.71
US$ 25.44
US$ 24.59
